Transaction:
- Unipath Specialty Laboratory Ltd (USLL), a leading diagnostic brand in Western India backed by the promoters of Intas Pharmaceuticals Ltd, has acquired 100% equity in Ravula Health Care Private Limited.
- The deal was structured in multiple independent tranches and marks Unipath’s third major inorganic expansion since FY24.
About Ravula Health Care Private Limited:
- Incorporated in April 2023, Ravula Health Care is a Hyderabad-based company, engaged in providing pathology, diagnostic, and imaging services.
About Unipath Specialty Laboratory Ltd (USLL):
- Incorporated in 2009 and headquartered in Ahmedabad, USLL operates across 11 states, managing 41 pathology labs through both owned and partnered models, and collaborating with 21 diagnostic centres.
- Offers over 3,000 tests annually across specialties including molecular pathology, hematopathology, and cytopathology.
Rationale:
- The acquisition strengthens Unipath’s presence in Southern India, particularly Telangana, complementing its existing operations across 11 states and supporting its goal of nationwide coverage.
- It aligns with Unipath’s broader strategy of becoming a pan-India diagnostic leader by expanding through targeted acquisitions and geographic diversification.
- It expands Unipath’s service offerings by adding imaging capabilities to its existing portfolio of over 3,000 pathology and diagnostic tests.
- With over 1 crore (10 million) tests conducted annually, Unipath aims to further scale its diagnostic volumes and operational reach through this acquisition.
- The integration of Ravula’s operations is expected to create synergies in infrastructure, technology, and logistics, enhancing service quality and cost efficiency across Unipath’s national network.
- This marks Unipath’s third strategic acquisition since FY24, following the purchase of Simira Diagnostics (100% stake), and SJM Centre (49%), showcasing its aggressive inorganic growth strategy.
Acknowledgements:
RBI Bulletin (www.bulletin.rbi.org.in), SEBI (www.sebi.gov.in), NSE (www.nseindia.com), BSE (www.bseindia.com)
Disclaimer:
This material has been prepared by the personnel in Vora Corporate Finance which is Investment Banking arm of Vora Management Consultancy Private Limited and looks after Mergers & Acquisitions (M&A), Private Equity (PE), Fund Raising, Debt syndication and Valuations and is based out of Ahmedabad, Gujarat, India. Any views or opinions expressed herein are solely that of individual authors and may differ from view of Vora Management Consultancy Private Limited. This material is proprietary to Vora Management Consultancy Private Limited and is for your personal use only. Any distribution, copy, reprints or forward to others is strictly prohibited.
This material captures the information based on information available in the public domain, public announcements and sources believed to be reliable. Analysis contained herein is based on publicly available information and appropriate assumptions. This material is intended merely to highlight market developments and is not intended to be comprehensive and does not constitute strategic, investment, legal or tax advice. In no event Vora Management Consultancy Private Limited be liable for any use by any party or for any decision made or action taken by any party in reliance upon, or for any inaccuracies or errors in, or omissions from, the information contained herein and such information may not be relied upon by you for evaluating any transaction.